Ipsen pays Lexicon $23m upfront for ex-US, Japan rights to PhIII drug
This article was originally published in Scrip
Ipsen of France has signed a deal with Texan firm Lexicon Pharmaceuticals for an exclusive license to commercialize telotristat etiprate outside North America and Japan, with a focus on the treatment of carcinoid syndrome. Lexicon, which bags $23m upfront under the deal, retains sole rights to commercialize telotristat etiprate in those territories.
You may also be interested in...
France’s Ipsen is preparing to launch Cabometyx in Europe this autumn and telotristat next year, and the business development expertise of its new CEO will be useful in replenishing its product portfolio.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.